Targeting signal transduction for disease therapy.
With the advance in the molecular understanding of disease processes, it has been appreciated that many diseases result from the malfunctions of signaling pathways. This recognition has led to intensive research and the development of therapies based on the interception of cellular signaling in diseased cells. In the past two years, success has been achieved using a blocker of the farnesylation of Ras as a tumor inhibitor, a JAK-2 blocker as an efficient inhibitor of recurrent pre-B cell acute lymphoblastic leukemia, and a platelet-derived growth factor receptor kinase as a blocker of restenosis.
Levitzki
A
A
Department of Biological Chemistry, Institute of Life Sciences, The Hebrew University of Jerusalem, Givat Ram, Jerusalem 91904, Israel. LEVITZKI@vms.huji.ac.il
D000818:Animals; D018844:Cyclin-Dependent Kinases / Q000037:antagonists & inhibitors; D004358:Drug Therapy; D019204:GTP-Binding Proteins / Q000037:antagonists & inhibitors; D006801:Humans; D009857:Oncogenes; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D018160:Receptors, Cytoplasmic and Nuclear / Q000037:antagonists & inhibitors; D015398:Signal Transduction / Q000187:drug effects* / Q000502:physiology; D014157:Transcription Factors / Q000037:antagonists & inhibitors; D018631:ras Proteins / Q000037:antagonists & inhibitors
D018160:Receptors, Cytoplasmic and Nuclear; D014157:Transcription Factors; D011505:Protein-Tyrosine Kinases; D018844:Cyclin-Dependent Kinases; D019204:GTP-Binding Proteins; D018631:ras Proteins